Research Study Results Bring Hope for Combating Debilitating Diseases - Research Report on Johnson & Johnson, AbbVie, Lilly,

   Research Study Results Bring Hope for Combating Debilitating Diseases -
      Research Report on Johnson & Johnson, AbbVie, Lilly, Novartis and
                               GlaxoSmithKline

PR Newswire

NEW YORK, June 12, 2013

NEW YORK, June 12, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Johnson
& Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV), Eli Lily & Co. (NYSE: LLY),
Novartis AG (NYSE: NVS) and GlaxoSmithKline plc. (NYSE: GSK). Today's readers
may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On June 6, 2013, Janssen R&D Ireland (Janssen), a part of the Janssen
Pharmaceutical Companies of Johnson & Johnson, released primary efficacy and
safety results from four Japanese Phase 3 clinical studies demonstrating the
use of the investigational NS3/4A protease inhibitor simeprevir (TMC435) led
to sustained virologic response 12 weeks after the end of treatment (SVR12) in
patients with genotype 1 hepatitis C, when administered once daily with
pegylated interferon and ribavirin. The four studies examined the use of
simeprevir in patients who were treatment naïve, as well as patients who were
non-responders to prior therapy or relapsed following treatment with pegylated
interferon with or without ribavirin. The studies supported the new drug
application for simeprevir, which was submitted to Japanese regulatory
authorities in February 2013. The Full Research Report on Johnson & Johnson -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/0ba3_JNJ]

--

AbbVie Inc. Research Report

On June 3, 2013, AbbVie Inc. (AbbVie) announced results from a Phase 1 study
of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor,
for the treatment of patients with relapsed/refractory chronic lymphocytic
leukemia (CLL), the most common leukemia in the United States, and
relapsed/refractory non-Hodgkin's lymphoma (NHL). The Phase 1 trial was
designed to assess the safety, determine the maximum tolerated dose and
recommended Phase 2 dose, and evaluate the pharmacokinetics of ABT-199 in
patients with relapsed/refractory CLL and NHL. Gary Gordon, M.D., divisional
Vice President of AbbVie's Oncology Clinical Development, said, "The ABT-199
data underscore AbbVie's commitment to the development of treatments for some
of the hardest-to-treat cancers like CLL and NHL. Early trials of ABT-199 have
shown the compound's potential in these hematological malignancies, which
support the continuation of its clinical development program." The Full
Research Report on AbbVie Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/2433_ABBV]

--

Eli Lily & Co. Research Report

On June 3, 2013, Eli Lilly & Co. (Lilly) announced results from its PRONOUNCE
trial of ALIMTA (pemetrexed for injection) for treatment of nonsquamous,
non-small cell lung cancer (NSCLC). The PRONOUNCE trial compared an ALIMTA
(pemetrexed), carboplatin doublet regimen to a paclitaxel, carboplatin and
bevacizumab triplet regimen. The study did not achieve its primary superiority
endpoint of improved progression-free survival without grade four adverse
events (G4PFS). No significant difference was observed between the treatment
arms for secondary endpoints of progression-free survival (PFS), overall
survival, overall response rate and disease control rate. Richard Gaynor,
M.D., Vice President of Product Development & Medical Affairs for Lilly
Oncology, said "The history of ALIMTA clinical evaluation - from histology to
its use in the maintenance therapy paradigm - encourages us to explore new
avenues to determine if we can improve patient outcomes. These data give us
additional insights that further inform the vast body of ALIMTA clinical
data." The Full Research Report on Eli Lily & Co. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/937b_LLY]

--

Novartis AG Research Report

On June 5, 2013, Novartis announced that it will present new data to show that
its Gilenya drug (fingolimod), the first once-daily oral therapy approved to
treat people with relapsing multiple sclerosis (RMS) has positively impacted
the key measures for multiple sclerosis (MS) - relapse rates, brain volume
loss, lesions and disability progression, at the 23rd meeting of the European
Neurological Society (ENS) on June 10, 2013. New findings from the TRANSFORMS
study showed that a greater proportion of patients were disease free after one
year on Gilenya treatment compared to interferon. Dr. Timothy Wright, Global
Head Development, Novartis Pharmaceuticals, commented, "These new analyses are
very encouraging in that they not only support the role of Gilenya as having
an anti-inflammatory effect but also highlight how Gilenya can improve the key
measures of this debilitating disease." The Full Research Report on Novartis
AG - including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/956c_NVS]

--

GlaxoSmithKline plc. Research Report

On June 6, 2013, GlaxoSmithKline plc. (GlaxoSmithKline) confirmed that a joint
advisory committee to the U.S. Food and Drug Administration (FDA) voted to
continue to make Avandia (rosiglitazone) available to appropriate patients
with the majority of the members voting to either modify or remove the Risk
Evaluation and Mitigation Strategy (REMS) program in place. Remaining members
voted to continue the REMS or withdraw Avandia from the US market. Dr. James
Shannon, GSK's Chief Medical Officer, commented, "We appreciate the
committee's thorough examination of the RECORD results and will continue to
work with the FDA as it considers the recommendation of the committee. We
continue to believe that Avandia is a safe and effective treatment option for
type 2 diabetes when used for the appropriate patient and in accordance with
labeling." Pending the FDA's decision, Avandia will be available through the
REMS program to physicians and appropriate patients as an option to help
control blood sugar in patients with type 2 diabetes. The Full Research Report
on GlaxoSmithKline plc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/2737_GSK]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquires, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.